Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Actinogen Medical ( (AU:ACW) ) has shared an update.
Actinogen Medical has reached a significant milestone in its XanaMIA phase 2b/3 trial for Alzheimer’s disease by enrolling its 100th participant, setting the stage for an interim analysis of safety and efficacy data. This analysis, conducted by an independent Data Monitoring Committee, will occur in January 2026, with final trial results expected in late 2026. The trial aims to demonstrate the safety and efficacy of Xanamem, potentially expediting its regulatory approval. The company is also preparing for discussions with the US FDA regarding approval pathways and may seek commercial partnerships for the next phase of development.
More about Actinogen Medical
Actinogen Medical is an ASX-listed biotechnology company focused on developing novel therapies for neurological and neuropsychiatric diseases linked to dysregulated brain cortisol. The company’s lead compound, Xanamem, is being developed as a promising therapy for Alzheimer’s Disease and Depression, with future plans to explore its use in Fragile X Syndrome and other neurological and psychiatric conditions.
YTD Price Performance: -12.00%
Average Trading Volume: 8,515,253
Technical Sentiment Signal: Sell
Current Market Cap: A$69.9M
Find detailed analytics on ACW stock on TipRanks’ Stock Analysis page.